BioCardia, Inc. Revenue
BioCardia, Inc. (BCDA) reported Revenue of $479.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-16.
Discontinued › Income Statement › Revenue
us-gaap:Revenues · last filed 2018-03-16
- BioCardia, Inc. revenues for the quarter ending 2017-12-31 was $100.00K, a 27.01% decline year-over-year.
- BioCardia, Inc. revenues for the quarter ending 2017-09-30 was $130.00K, a 11.11% increase year-over-year.
- BioCardia, Inc. revenues for the quarter ending 2017-06-30 was $112.00K, a 22.22% decline year-over-year.
- BioCardia, Inc. revenues for the quarter ending 2017-03-31 was $137.00K, a 23.03% decline year-over-year.
- BioCardia, Inc. revenues for fiscal 2017 was $479.00K, a 16.84% decline from fiscal 2016.
- BioCardia, Inc. revenues for fiscal 2016 was $576.00K, a 36.28% decline from fiscal 2015.
- BioCardia, Inc. revenues for fiscal 2015 was $904.00K.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2017-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $230.00K derived: sum of 2 quarters · filed 2018-03-16 | $342.00K derived: sum of 3 quarters · filed 2018-03-16 | $479.00K 10-K · filed 2018-03-16 |
| 2017-09-30 | $130.00K 10-Q · filed 2017-11-09 | $242.00K derived: sum of 2 quarters · filed 2017-11-09 | $379.00K 10-Q · filed 2017-11-09 | $516.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-06-30 | $112.00K 10-Q · filed 2017-08-14 | $249.00K 10-Q · filed 2017-08-14 | $386.00K derived: sum of 3 quarters · filed 2018-03-16 | $503.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-03-31 | $137.00K 10-Q · filed 2017-05-11 | $274.00K derived: sum of 2 quarters · filed 2018-03-16 | $391.00K derived: sum of 3 quarters · filed 2018-03-16 | $535.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-12-31 | $137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $254.00K derived: sum of 2 quarters · filed 2018-03-16 | $398.00K derived: sum of 3 quarters · filed 2018-03-16 | $576.00K 10-K · filed 2018-03-16 |
| 2016-09-30 | $117.00K 10-Q · filed 2017-11-09 | $261.00K derived: sum of 2 quarters · filed 2017-11-09 | $439.00K 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $144.00K 10-Q · filed 2017-08-14 | $322.00K 10-Q · filed 2017-08-14 | ||
| 2016-03-31 | $178.00K 10-Q · filed 2017-05-11 | |||
| 2015-12-31 | $904.00K 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |